Long QT Syndrome (LQTS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Long QT Syndrome (LQTS) Market Outlook
Thelansis’s “Long QT Syndrome (LQTS)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Long QT Syndrome (LQTS) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Long QT Syndrome (LQTS) Overview
Long QT
Syndrome (LQTS) could be a congenital or acquired heterogeneous syndrome that
predisposes patients to arrhythmogenic syncope, seizures, and sudden cardiac
death (SCD). Clinically, LQTS shows a lifelong asymptomatic state with no
electrocardiographic (ECG) findings, and it is generally an asymptomatic state
for life. Frequent and recurrent LQTS triggers emotional or physical stress and
leads to SCD. The electrocardiographic QT interval represents the cardiac
action potential’s depolarization and repolarization phases. The interplay of
several ion channels determines the action potential duration. Decreases in
repolarizing outward K+ currents or increases in depolarizing inward sodium or
calcium currents can prolong the QT interval, thus representing a
pathophysiological substrate for LQTS. KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A
(LQT3) are the most common LQTS genes, accounting for ≈90% of all
genotype-positive cases. Heterozygous KCNQ1 mutations cause the dominant RW
LQT1 syndrome and account for most disease-causing variants. Homozygous
mutations in KCNQ1, or compound heterozygous mutations, cause the recessive JLN
variant characterized by deafness because of the reduced IKs in the inner ear.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment